Erlotinib in previously treated non-small-cell lung cancerSHEPHERD, Frances A; PEREIRA, José Rodrigues; VAN KOOTEN, Maximiliano et al.The New England journal of medicine. 2005, Vol 353, Num 2, pp 123-132, issn 0028-4793, 10 p.Article

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy : National cancer institute of canada clinical trials group study BR.20ARNOLD, Andrew M; SEYMOUR, Lesley; GOSS, Glen-Wood et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4278-4284, issn 0732-183X, 7 p.Article

Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14PRITCHARD, Kathleen I; SHEPHERD, Lois E; O'REILLY, Susan E et al.Journal of clinical oncology. 2011, Vol 29, Num 29, pp 3869-3876, issn 0732-183X, 8 p.Article

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non- small-cell lung cancer: A phase III trial of the Italian gemvin investigators and the national Cancer institute of Canada clinical trials groupGRIDELLI, Cesare; GALLO, Ciro; FINDLAY, Brian et al.Journal of clinical oncology. 2003, Vol 21, Num 16, pp 3025-3034, issn 0732-183X, 10 p.Article

Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non―Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10BUTTS, Charles A; KEYUE DING; CORMIER, Yvon et al.Journal of clinical oncology. 2010, Vol 28, Num 1, pp 29-34, issn 0732-183X, 6 p.Article

Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA TrialGOODWIN, Pamela J; SEGAL, Roanne J; LEVINE, Mark et al.Journal of clinical oncology. 2014, Vol 32, Num 21, pp 2231-2239, issn 0732-183X, 9 p.Article

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialMITTMANN, Nicole; AU, Heather-Jane; FINDLAY, Brian et al.Journal of the National Cancer Institute. 2009, Vol 101, Num 17, pp 1182-1192, issn 0027-8874, 11 p.Article

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerGOLDBERG, Richard M; SARGENT, Daniel J; MORTON, Roscoe F et al.Journal of clinical oncology. 2004, Vol 22, Num 1, pp 23-30, issn 0732-183X, 8 p.Article

Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancerMEYERHARDT, Jeffrey A; SLOAN, Jeffrey A; SARGENT, Daniel J et al.Cancer epidemiology, biomarkers & prevention. 2005, Vol 14, Num 6, pp 1402-1410, issn 1055-9965, 9 p.Article

Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer : N9741SANOFF, Hanna K; SARGENT, Daniel J; CAMPBELL, Megan E et al.Journal of clinical oncology. 2008, Vol 26, Num 35, pp 5721-5727, issn 0732-183X, 7 p.Article

Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer : A north American intergroup trialMEROPOL, Neal J; GOLDBERG, Richard M; SARGENT, Daniel J et al.Journal of clinical oncology. 2006, Vol 24, Num 21, issn 0732-183X, 3322-3324,3347-3353 [10 p.]Article

Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741MCLEOD, Howard L; SARGENT, Daniel J; GROTHEY, Axel et al.Journal of clinical oncology. 2010, Vol 28, Num 20, pp 3227-3233, issn 0732-183X, 7 p.Article

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen : A companion study to NCIC CTG MA.17PEREZ, Edith A; JOSSE, Robert G; SHIFANG LIU et al.Journal of clinical oncology. 2006, Vol 24, Num 22, pp 3629-3635, issn 0732-183X, 7 p.Article

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin : results from intergroup trial N9741DELAUNOIT, Thierry; GOLDBERG, Richard M; GREEN, Erin et al.Cancer. 2004, Vol 101, Num 10, pp 2170-2176, issn 0008-543X, 7 p.Article

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : Intergroup trial n9741 in first-line treatment of metastatic colorectal cancerASHLEY, Amanda C; SARGENT, Daniel J; PITOT, Henry C et al.Cancer. 2007, Vol 110, Num 3, pp 670-677, issn 0008-543X, 8 p.Article

Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer : Results from intergroup N9741DY, Grace K; KROOK, James E; POCKAJ, Barbara A et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3469-3474, issn 0732-183X, 6 p.Article